<DOC>
	<DOCNO>NCT02042170</DOCNO>
	<brief_summary>The purpose study ass dose requirement establish efficacy SR-hGH idiopathic short stature patient ( ISS ) . This phase II study design multi-center , randomize , active comparator-controlled , parallel , open-label . 45 patient randomize three arm 1:1:1 ratio , two arm Sr-hGH one daily hGH . Two dose Sr-hGH administer , 0.5 0.7mg/kg/week . And arm receive daily hGH 0.37 mg/kg/week . Patients Sr-hGH group inject specific day every week 26 week . And patient randomize daily hGH group inject 6 day week . Patients visit study center five time , firstly screen ( Visit 1 ) , randomization ( Visit 2 ) , 13th dosing ( Visit 3 ) , 26th dosing ( Visit 4 ) , finally follow-up ( Visit5 ) .</brief_summary>
	<brief_title>Efficacy Safety Study Sr-hGH Comparison With Daily hGH ISS Patients</brief_title>
	<detailed_description />
	<mesh_term>Hormones</mesh_term>
	<criteria>Criteria old equal age 4 prepubertal ( Tanner 's stage I ) young bone age 9 female ; 11 male less 3 year difference bone chronological age confirm idiopathic short stature</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>14 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>